Interstitial lung diseases (ILDs) comprise a heterogeneous group of disorders characterized by varying degrees of inflammation and fibrosis, affecting the lung parenchyma. Despite the diverse etiologies, these disorders share similar clinical, radiological, and histopathological features, making diagnosis and management challenging.
ILDs can be classified based on etiology into idiopathic, secondary to systemic diseases, and those caused by environmental exposures. Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias and is marked by progressive fibrosis. The secondary ILDs can be due to connective tissue diseases, drugs, or radiation therapy. Occupational and environmental ILDs are due to inhalation of harmful substances like asbestos or silica.
Patients typically present with progressive dyspnea and non-productive cough. Physical examination may reveal bibasilar inspiratory crackles and finger clubbing. High-resolution computed tomography (HRCT) is the imaging modality of choice, often showing reticular abnormalities, honeycombing, and ground-glass opacities. Lung biopsy may be needed in certain cases for definitive diagnosis.
Treatment is largely based on the underlying cause. In IPF, antifibrotic drugs like pirfenidone and nintedanib have shown to slow disease progression. For ILDs secondary to connective tissue diseases, immunosuppressive therapy is the mainstay. Lung transplantation may be considered in advanced cases. Prognosis varies widely, with IPF having a median survival of 2-3 years from diagnosis.
Understanding the intricate facets of ILDs is crucial for timely diagnosis and effective management. As healthcare professionals, staying abreast of the latest advancements in this field can significantly impact patient outcomes. Future research focusing on the pathogenesis and novel therapeutic targets is the need of the hour to improve the prognosis of these debilitating disorders.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation